Grufity logoGrufity logo

SGEN

122.41USD+1.39(+1.15%)Market Closed

Seagen Inc.

Market Summary

USD122.41+1.39Market Closed
1.15%

SGEN Alerts

SGEN Stock Price

RSI Chart

Valuation

Market Cap

24.0B

Price/Earnings

-37.73

Price/Sales

12.89

Price/Cashflow

-36.53

MarketCap/EBT

-37.8

Price/Sales

Profitability

EBT Margin

-34.09%

Return on Equity

-22.57%

Return on Assets

-17.59%

Fundamentals

Revenue

Revenue (TTM)

1.9B

Revenue Y/Y

20.34%

Revenue Q/Q

2.57%

Earnings

Earnings (TTM)

-636.8M

Earnings Y/Y

35.06%

Earnings Q/Q

-41.53%

Price Action

52 Week Range

105.43183.00
(Low)(High)

Last 7 days

-0.8%

Last 30 days

-5.2%

Last 90 days

-19.7%

Trailing 12 Months

-22.8%

Financial Health

Current Ratio

3.8

Investor Care

Shares Dilution (1Y)

1.54%

Diluted EPS (TTM)

-3.45

Peers (Alternatives to Seagen)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
146.5B
26.3B
6.86% 46.41%
22.27
5.55
2.18% 21.86%
99.4B
27.1B
14.32% 33.87%
24.02
3.61
-1.26% -54.91%
59.1B
23.0B
22.70% -39.52%
4.2
2.57
227.55% 302.16%
41.3B
10.4B
7.38% 30.80%
14.4
3.98
-6.64% 85.32%
11.1B
1.4B
3.89% 57.25%
905.99
8.52
29.86% -86.92%
MID-CAP
3.7B
112.4M
6.18% -26.69%
-12.87
32.5
-41.50% -607.58%
3.4B
-
7.39% -35.47%
-14.65
59.51
215916.67% 21.41%
2.1B
68.3M
4.34% -60.25%
-8.33
30.98
42.18% -19.70%
2.0B
432.8M
45.87% -20.63%
29.99
4.9
1042.97% 128.67%
SMALL-CAP
1.8B
1.8B
-19.41% -89.80%
-1.22
1.39
53.41% -22.97%
1.6B
69.7M
-4.82% -76.34%
-3.15
20.84
745.14% -7.72%
891.0M
3.2M
5.78% -29.88%
-6.7
275.59
11.14% -46.59%
692.0M
114.2M
-14.32% -56.80%
-4.02
6.06
-17.11% -27.41%
458.1M
-
-17.48% -90.68%
-13.56
44.06
522.71% -129.91%
218.9M
-
-15.58% -80.57%
-2.36
609.63
-71.03% -64.56%

Financials for Seagen

Income Statement (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Revenue4.9%1,8641,7781,6691,5741,746
  S&GA Expenses3.8%816786731716664
  R&D Expenses-5.5%1,2911,3651,2961,2291,141
Earnings Before Taxes14.1%-635.46-739.67-689.52-675.70-332.85
Net Income13.9%-636.76-739.80-689.54-674.47-332.75
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Assets-0.3%3,6193,6303,6173,7203,978
  Current Assets-0.7%2,7602,7792,7712,8693,115
    Cash Equivalents1.0%368365261425685
  Inventory14.3%365319276201181
  Net PPE5.2%230219214210209
  Goodwill0%275275275275275
  Current Liabilities19.3%726609531569698
Shareholder's Equity-3.8%2,8222,9332,9983,0653,165
  Retained Earnings-10.5%-2,006.18-1,815.36-1,680.53-1,544.04-1,369.41
  Additional Paid-In Capital1.5%4,7474,6784,6084,533-
Accumulated Depreciation-212----
Shares Outstanding0.5%185184184183183
* denotes actual numbers (not divided by Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Cashflow From Operations-11.5%-657.69-589.82-590.49-499.01-26.48
  Share Based Compensation7.1%209195179173161
Cashflow From Investing-43.3%266469394289-1,035.67
Cashflow From Financing-4.7%82868578829

Risks

What is the probability of a big loss on SGEN?

72.3%


Probability that Seagen stock will be more than 20% underwater in next one year

55.4%


Probability that Seagen stock will be more than 30% underwater in next one year.

0%


Probability that Seagen stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does SGEN drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Seagen was unfortunately bought at previous high price.

Returns

Cumulative Returns on SGEN

16.8%


10-Year Cumulative Returns

17.3%


7-Year Cumulative Returns

15.5%


5-Year Cumulative Returns

1.0%


3-Year Cumulative Returns

What are the long-term rolling returns for SGEN?

FIve years rolling returns for Seagen.

Which funds bought or sold SGEN recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2022-11-23
Toroso Investments, LLC
ADDED
2.77
-108,000
417,000
0.02%
2022-11-23
Eagle Bay Advisors LLC
UNCHANGED
-
-539
3,000
-%
2022-11-22
Seaport Global Advisors, LLC
-
-
-239,000
214,000
0.87%
2022-11-22
Capital Impact Advisors, LLC
-
-
-177,000
317,000
0.32%
2022-11-22
CVA Family Office, LLC
-
-
-2,000
7,000
-%
2022-11-22
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
NEW
-
4,952,000
4,952,000
0.06%
2022-11-21
FourThought Financial, LLC
-
-
-1,000
2,000
-%
2022-11-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
-
-
-9,428,000
30,818,000
0.05%
2022-11-18
Industrial Alliance Investment Management Inc.
ADDED
2.6
-637,000
2,448,000
0.07%
2022-11-18
National Pension Service
REDUCED
-7.99
-10,672,000
25,582,000
0.05%

1–10 of 42

Latest Funds Activity

Are funds buying SGEN calls or puts?
Are funds bullish or bearish(Calls - Puts)?
No. of funds that own SGEN

Seagen News

MarketWatch

Incyte Corp. stock rises Friday, outperforms market.40 hours ago

SGEN Fair Value

Recent SEC filings of Seagen

View All Filings
Date Filed Form Type Document
Nov 18, 2022
4
Insider Trading
Nov 18, 2022
8-K
Current Report
Nov 18, 2022
CT ORDER
CT ORDER
Nov 16, 2022
4
Insider Trading
Nov 15, 2022
4
Insider Trading
Nov 14, 2022
4
Insider Trading
Nov 14, 2022
4
Insider Trading
Nov 14, 2022
4
Insider Trading
Nov 10, 2022
3
Insider Trading
Nov 10, 2022
3
Insider Trading

Latest Insider Trading transactions for SGEN

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-11-17
LIU JEAN I
SOLD
-1,092,060
131.052
-8,333
Chief Legal Officer
2022-11-17
LIU JEAN I
ACQUIRED
284,989
34.2
8,333
Chief Legal Officer
2022-11-14
LIU JEAN I
ACQUIRED
99,994.9
76.86
1,301
Chief Legal Officer
2022-11-11
GRYSKA DAVID W
SOLD
-968,220
129.096
-7,500
-
2022-11-09
SWAIN SANDRA M
ACQUIRED
-
-
778
-
2022-11-09
Epstein David R
ACQUIRED
-
-
107,389
Chief Executive Officer
2022-10-17
DANSEY ROGER D
ACQUIRED
745,421
74.5421
10,000
Interim CEO & CMO
2022-10-17
DANSEY ROGER D
SOLD
-1,350,000
135
-10,000
Interim CEO & CMO
2022-08-31
ROMP CHARLES R
SOLD
-174,952
154.415
-1,133
EVP, Commercial
2022-08-31
SIMPSON TODD E
SOLD
-646,379
154.415
-4,186
Chief Financial Officer

1–10 of 50

Roger D. Dansey
2680
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70 for various cancer diseases. Seagen Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.

SGEN Income Statement

2022-09-30
Condensed Consolidated Statements of Comprehensive Loss - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Revenues:    
Total revenues$ 510,300$ 424,060$ 1,434,262$ 1,144,520
Costs and expenses:    
Cost of sales108,12282,650301,848224,875
Research and development384,605459,092986,518924,378
Selling, general and administrative210,378180,281604,862505,253
Total costs and expenses703,105722,0231,893,2281,654,506
Loss from operations(192,805)(297,963)(458,966)(509,986)
Investment and other income, net4,2785,22847911,255
Loss before income taxes(188,527)(292,735)(458,487)(498,731)
Provision for income taxes2,2891,1123,6501,112
Net loss$ (190,816)$ (293,847)$ (462,137)$ (499,843)
Net loss per share - basic (in dollars per share)$ (1.03)$ (1.61)$ (2.51)$ (2.75)
Net loss per share - diluted (in dollars per share)$ (1.03)$ (1.61)$ (2.51)$ (2.75)
Shares used in computation of per share amounts - basic (in shares)184,792182,303184,199181,696
Shares used in computation of per share amounts - diluted (in shares)184,792182,303184,199181,696
Comprehensive loss:    
Net loss$ (190,816)$ (293,847)$ (462,137)$ (499,843)
Other comprehensive income:    
Unrealized (loss) gain on securities available-for-sale, net of tax(875)37(4,472)(10)
Foreign currency translation gain (loss)3,363(6)6,288268
Total other comprehensive income2,488311,816258
Comprehensive loss(188,328)(293,816)(460,321)(499,585)
Net product sales    
Revenues:    
Total revenues428,089366,4591,242,8891,016,385
Royalty revenues    
Revenues:    
Total revenues43,90441,028111,194104,542
Collaboration and license agreement revenues    
Revenues:    
Total revenues$ 38,307$ 16,573$ 80,179$ 23,593

SGEN Balance Sheet

2022-09-30
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 362,601$ 424,834
Short-term investments1,401,1011,735,202
Accounts receivable, net486,755389,256
Inventories364,970200,663
Prepaid expenses and other current assets144,192119,239
Total current assets2,759,6192,869,194
Property and equipment, net230,302210,073
Operating lease right-of-use assets49,30857,889
Intangible assets, net243,332260,593
Goodwill274,671274,671
Other non-current assets61,84647,184
Total assets3,619,0783,719,604
Current liabilities:  
Accounts payable144,499114,824
Accrued liabilities and other581,499454,030
Total current liabilities725,998568,854
Long-term liabilities:  
Operating lease liabilities, long-term46,70356,665
Other long-term liabilities24,56628,946
Total long-term liabilities71,26985,611
Commitments and contingencies
Stockholders’ equity:  
Preferred stock, $0.001 par value, 5,000 shares authorized; none issued00
Common stock, $0.001 par value, 250,000 shares authorized; 185,234 shares issued and outstanding at September 30, 2022 and 183,381 shares issued and outstanding at December 31, 2021185183
Additional paid-in capital4,824,8074,607,816
Accumulated other comprehensive income2,9951,179
Accumulated deficit(2,006,176)(1,544,039)
Total stockholders’ equity2,821,8113,065,139
Total liabilities and stockholders’ equity$ 3,619,078$ 3,719,604